Benjamin Ebert is the New President and CEO of Dana-Farber Cancer Center

Benjamin Ebert, MD, PhD chair of Department of Medical Oncology at the Dana-Farber Cancer Center was recently appointed as the President and CEO of Dana-Farber Cancer Center.

Benjamin Ebert shared on LinkedIn:

“I’m extraordinarily honored to be appointed the next president and CEO of Dana-Farber and to build on the exceptional leadership and accomplishments of Laurie Glimcher, MD.

Dana-Farber is truly a remarkable organization and a global leader in innovation, and in caring and advocating for cancer patients. Together with our executive leadership team, I will continue to advance a patient-first model as we open this new chapter.”

People shared their congratulations on Social Media:

Michelle Monti:

“Leadership transition happening at my company, Dana-Farber Cancer Institute. Luckily, the torch is being handed from one great leader to another!”

Ian Matthew-Clayton:

“At Dana-Farber we are on an incredible journey to defy cancer and Dr. Laurie Glimcher has led us far and Dr. Benjamin Ebert will take us further!”

Ruben Mesa: 

“Good luck Ben! You will do an amazing job leading such a legendary Cancer organization into its new future!”

Raquel Castellanos:

“Congratulations to recent CICR Steering Committee member and AACR Fellow of the AACR Academy Benjamin L. Ebert on his appointment as next president and CEO of Dana-Farber.”

Giada Bianchi:

“So well deserved! Congrats Ben!!! Lucky to have you.”

For more posts like this, visit oncodaily.com

Benjamin L. Ebert is the George P. Canellos Professor of Medicine at Harvard Medical School and Chair of Medical Oncology at Dana-Farber Cancer Institute. He is a Howard Hughes Medical Institute Investigator and an Institute Member of the Broad Institute. Ebert, a member of the National Academy of Medicine, American Society for Clinical Investigation, and the Association of American Physicians, focuses on the molecular basis and treatment of hematologic malignancies, especially myelodysplastic syndromes (MDS).